Dapivirine Ring: The Case for Action

Women need HIV prevention options they can control. IPM's monthly dapivirine ring is the first discreet, long-acting product designed specifically for women that has been clinically shown to reduce women's HIV risk. 

This report is for national governments, donors, implementers, and advocates who are planning for the potential launch of the ring, pending regulatory approval. 

Among the report's main findings: 

  • The dapivirine ring could prevent over half a million new HIV infections in sub-Saharan Africa by 2030.
  • The ring would give women a way to control their own health and protect themselves against HIV without partner involvement.
  • The dapivirine ring offers four major benefits: high user acceptability, efficacy against HIV transmission, a good safety profile and ease-of-use. 

Authored by FSG, a member of the OPTIONS Consortium, a five-year USAID and PEPFAR initiative